2024 ESMO Congress: Black Diamond Therapeutics presents real-world NSCLC patient outcomes with non-classical mutations.

Black Diamond Therapeutics presented findings at the ESMO Congress 2024, showcasing real-world treatment practices and patient outcomes for newly diagnosed non-small cell lung cancer (NSCLC) patients with non-classical mutations. The presentation highlights the importance of understanding treatment approaches and their effectiveness in this specific patient population, contributing valuable insights to ongoing cancer research and care practices.

September 14, 2024
4 Articles

Further Reading